Arcus Biosciences shares are trading higher after the company announced new data from the ARC-20 platform study evaluating casdatifan, an investigational next-generation HIF-2α inhibitor, alone or in combination, as a first-, second-, and late-line treatment for clear cell renal cell carcinoma.